News | January 10, 2024
Tata 1mg and Vitonnix UK get into an exclusive partnership in India
Launch innovative vitamin sublingual sprays
Launch innovative vitamin sublingual sprays
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens
Comprehensive clinical development programs being initiated for each investigational candidate
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
Innovent will supply sintilimab for the collaborated clinical trial
The LyondellBasell CirculenRenew polymers are made from renewable feedstocks derived from bio-based wastes
Furthering cell therapy ambition across oncology and autoimmune diseases
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
Subscribe To Our Newsletter & Stay Updated
